Arbor Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Arbor Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010843
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arbor Pharmaceuticals LLC (Arbor) is a healthcare products provider that develops prescription products for the hospital, cardiovascular and pediatric segments. The company offers licensing, manufacturing, development and commercialization of late-stage prescription products. It also offers generic prescription and development stage products. Arbor’s prescription products comprise edarbi, edarbyclor, bidil, nymalize, eryped, and erythromycin group of products. It offers products used in treatment areas including cardiovascular, emergency, pediatrics, psychiatry and endocrinology diseases. The company offers its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US.

Arbor Pharmaceuticals LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
Private Equity 13
KKR to Acquire Minority Stake in Arbor Pharma 13
Partnerships 14
Debiopharm Enters into Distribution Agreement with Arbor Pharma 14
Licensing Agreements 15
Dr. Reddy’s Labs Enters into Licensing Agreement with XenoPort for XP23829 15
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 16
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 17
Equity Offering 18
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 18
XenoPort Completes Public Offering Of Shares For US$85.8 Million 19
XenoPort Completes Public Offering Of Common Stock For US$46 Million 20
Debt Offering 21
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 21
Acquisition 23
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 23
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24
Arbor Pharmaceuticals LLC – Key Competitors 26
Arbor Pharmaceuticals LLC – Key Employees 27
Arbor Pharmaceuticals LLC – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arbor Pharmaceuticals LLC, Deals By Therapy Area, 2011 to YTD 2017 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
KKR to Acquire Minority Stake in Arbor Pharma 13
Debiopharm Enters into Distribution Agreement with Arbor Pharma 14
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 15
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 16
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 17
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 18
XenoPort Completes Public Offering Of Shares For US$85.8 Million 19
XenoPort Completes Public Offering Of Common Stock For US$46 Million 20
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 21
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 23
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24
Arbor Pharmaceuticals LLC, Key Competitors 26
Arbor Pharmaceuticals LLC, Key Employees 27
Arbor Pharmaceuticals LLC, Subsidiaries 28

★海外企業調査レポート[Arbor Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Naked Wines plc (WINE):企業の財務・戦略的SWOT分析
    Naked Wines plc (WINE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Thai Union Frozen Products Public Company Limited:企業の戦略・SWOT・財務情報
    Thai Union Frozen Products Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Thai Union Frozen Products Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • Kesoram Industries Ltd:企業の戦略・SWOT・財務情報
    Kesoram Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Kesoram Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Genuine Parts Company:企業の戦略・SWOT・財務分析
    Genuine Parts Company - Strategy, SWOT and Corporate Finance Report Summary Genuine Parts Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • U.S. Energy Corp (USEG):企業の財務・戦略的SWOT分析
    Summary U.S. Energy Corp (US Energy) is an oil and gas company that offers exploration, development and production of oil and natural gas properties. The company provides maintenance of mineral properties. It operates its oil and gas prospects located in the Williston Basin of North Dakota, the Eagl …
  • Blueprint Medicines Corp (BPMC)-医療機器分野:企業M&A・提携分析
    Summary Blueprint Medicines Corp (Blueprint) is a biotechnology company that develops drugs for the treatment of cancers. The company discovers selective kinase inhibitors for genomically defined cancer subsets. Its pipeline products include BLU-285, for treatment resistant gastrointestinal stromal …
  • Barclays:企業の戦略・SWOT・財務情報
    Barclays - Strategy, SWOT and Corporate Finance Report Summary Barclays - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Tuas Power Ltd:企業の戦略的SWOT分析
    Tuas Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Allied International Corporation:企業の戦略・SWOT・財務情報
    Allied International Corporation - Strategy, SWOT and Corporate Finance Report Summary Allied International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Proteus Digital Health Inc:企業の戦略的SWOT分析
    Proteus Digital Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Almac Diagnostics Ltd:製品パイプライン分析
    Summary Almac Diagnostics Ltd (Almac Diagnostics), formerly ArraDx Ltd, a subsidiary of Almac Group Ltd, medical diagnostic company that discovers, develops and commercializes diagnostic tests including companion diagnostics. The company’s products pipeline includes ColDx, DDRD, AADx, prostate Dx, a …
  • Acerinox Group:企業の戦略・SWOT・財務情報
    Acerinox Group - Strategy, SWOT and Corporate Finance Report Summary Acerinox Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Meiji Yasuda Life Insurance Company:企業の戦略・SWOT・財務情報
    Meiji Yasuda Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Meiji Yasuda Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Medical Prognosis Institute AS (MPI):医療機器:M&Aディール及び事業提携情報
    Summary Medical Prognosis Institute A/S (MPI) is a precision medicine provider that offers cancer treatment solutions. The company offers drug response prediction platforms that provide tools for rationalized drug development and personalized medicine. It offers lead compound selection, drug rescue …
  • Spirit AeroSystems Holdings, Inc.:企業のM&A・事業提携・投資動向
    Spirit AeroSystems Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Spirit AeroSystems Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Cynosure Inc (CYNO):企業の財務・戦略的SWOT分析
    Summary Cynosure Inc (Cynosure), a subsidiary of Hologic Inc, is a developer, manufacturer and supplier of light-based aesthetic and medical treatment systems. Its products facilitate non-invasive body contouring, skin revitalization and scar reduction, cellulite reduction, hair removal, gynecologic …
  • ContourGlobal LP-エネルギー分野:企業M&A・提携分析
    Summary ContourGlobal L.P. (CGLP) is an energy company that owns and operates of power generation assets. It develops, acquires and operates electric power and district heating businesses. The company develops and operates large central power plants in emerging markets to support the growth of the n …
  • Oracle Corporation:企業の戦略・SWOT・財務情報
    Oracle Corporation - Strategy, SWOT and Corporate Finance Report Summary Oracle Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Marui Group Co., Ltd.:企業の戦略・SWOT・財務情報
    Marui Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Marui Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Goldman Sachs Group Inc (GS):企業の財務・戦略的SWOT分析
    The Goldman Sachs Group Inc (GS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆